Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial

David J Maron1, Jonathan D Newman2, Rebecca Anthopolos3

  • 1Department of Medicine, Stanford Prevention Research Center and Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.

Insights

Achieving guideline-directed medical therapy (GDMT) goals for chronic coronary disease (CCD) is linked to fewer cardiovascular events. Early and sustained attainment of goals, particularly systolic blood pressure, significantly reduces risks.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Clinical Research

Background:

  • Guideline-directed medical therapy (GDMT) is recommended for chronic coronary disease (CCD) patients, but achieving all goals is uncommon.
  • The impact of achieving specific GDMT goals and their timing on cardiovascular events remains uncertain.

Purpose of the Study:

  • To investigate the relationship between achieving specific GDMT goals and clinical outcomes in patients with CCD.
  • To determine the relative importance and timing of GDMT goal attainment for cardiovascular event reduction.

Main Methods:

  • Observational study of 5,179 participants with CCD from the ISCHEMIA trial.
  • Primary outcome: cardiovascular death or myocardial infarction (MI).
  • GDMT goals included systolic blood pressure (SBP) <130 mmHg, LDL-C <70 mg/dL, smoking cessation, and antiplatelet therapy.
  • Bayesian joint modeling analyzed longitudinal goal status and time-to-event data.

Main Results:

  • Only 12% of participants met all 4 GDMT goals at baseline.
  • Achieving all 4 GDMT goals at baseline was associated with an 8.7% 4-year cumulative event rate for CV death/MI, versus 24.5% for no goals met.
  • Systolic blood pressure (SBP) goal attainment showed a significant absolute event reduction (-5.1%), and each 10 mmHg lower SBP was linked to a 10% relative risk reduction in CV death/MI.

Conclusions:

  • Early attainment and maintenance of GDMT goals, especially SBP control, are associated with reduced cardiovascular events in CCD patients.
  • Meeting all 4 GDMT goals at baseline was associated with an absolute 16% reduction in CV deaths and MIs compared to meeting none.
Abstract

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
216
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
429
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354